Brazil receives Pfizer’s request for emergency use of Paxlovid

RIO DE JANEIRO, BRAZIL – The Brazilian Health Regulatory Agency (ANVISA) on Wednesday, February 16, received a request from U.S. pharmaceutical company Pfizer for the emergency use of Paxlovid, a drug to treat Covid-19, the regulator reported.

Paxlovid is currently in use in the United States, China, Canada, Japan, and European Union countries. The data presented by the laboratory that the drug can reduce hospitalization and deaths by up to 89% when administered early in the infection will now be reviewed by ANVISA.

The deadline for the assessment of the request will be 30 days, and within 24 hours “the documents submitted will be reviewed to ensure that they are in compliance with the required information,” and the technical analysis of the antiviral drug for oral use will begin.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error